Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UMBRELLA trial of tislelizumab in patients with molecular residual disease after curative treatment
2023-503316-33-00Phase 3Authorised
- Sponsor
- Gustave Roussy
- Start
- Mar 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in non-small cell lung cancer (NSCLC), colorectal cancer (CRC), pancreatic cancer (PC) and 1 more comparing Tislelizumab with Placebo / saline control (2 arms). Primary endpoint: Disease-free survival in MRD-positive patients. Planned start Mar 2024; status: authorised.
02
Drugs
tislelizumab
03
Conditions
non-small cell lung cancer (NSCLC)colorectal cancer (CRC)pancreatic cancer (PC)soft tissue sarcoma (STS)
Beyond the preview
Go deeper on 2023-503316-33-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-503316-33-00.